인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
To determine a rational preclinical formulation strategy for preclinical research, scientists should consider with their own work-flow and physicochemical properties acquired by each discovery stage. In general, physicochemical properties such as ionization states and kinetic solubility could be obtained in the early discovery stage. However, more detailed properties such as equilibrium solubility, pKa, pH-solubility and cLog P/D could be confirmed at the late discovery stage. For these reasons, it was hard to decide which kinds of formulation were most suitable for candidates. Therefore, the primary objective of this review was to figure out preclinical formulation strategy based on drug discovery stage, and propose case-study with real case for application. Preclinical formulation strategy of previously approved drug that has similar characteristics usually was used in early drug discovery stage. Especially if information of drug characteristics was limited, researchers were able to consider that it was alternative methods to make suspension with surfactant and cyclodextrin-drug complexation method. For late discovery stage, there are several ways to consider the characteristic of various physicochemical properties such as pH-adjustment, solubilization (using by co-solvent, surfactant) and combination of pH-adjustment and solubilization. As drug discovery work-flow are different among pharmaceutical companies, making preclinical formulation strategy from early stage of drug discovery is important for increment of success ratio of new drug development. This review could guide researchers which preclinical formulation is appropriate by suggesting rational strategy.
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지정보가 잘못된 경우 알려주세요!
목차
등록된 정보가 없습니다.
참고문헌
참고문헌 신청최근 본 자료
